Items where Division is "Bacteriology" and Year is 2023

Group by: Creators | Item Type | No Grouping
Number of items: 11.

Balasubramanian, M and Munishankar, S and Thiruvenkadam, K and Dusthackeer, A (2023) Myoinositol and methyl stearate increases rifampicin susceptibility among drug- resistant Mycobacterium tuberculosis expressing Rv1819c. Myoinositol and methyl stearate increases rifampicin susceptibility among drug- resistant Mycobacterium tuberculosis expressing Rv1819c, 101(4) (883-95).

Christy Rosaline, Nirmal and Sam Ebenezer, Rajadas and Balasubramanian, Mahizhaveni and Magdaline, Divya and Chilamakuru, Naresh Babu and Rajkumar, Dinesh and A, Radhakrishnan and Ramalingam, Paraman and Mondal, Rajesh and Azger, Dustackeer (2023) Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c. Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c, 157 (2). pp. 192-203. ISSN 0971-5916

Gopalaswamy, R and Rajendran, P and Shanmugam, S (2023) Comprehensive assessment of invalid and indeterminate results in Truenat MTB-RIF testing across sites under the national TB elimination program of India. Comprehensive assessment of invalid and indeterminate results in Truenat MTB-RIF testing across sites under the national TB elimination program of India, 11 (1255756).

Quinn, Frederick and Mondal, Rajesh and Dusthackeer V. N., Azger and Kannan, Palaniyandi and Singh, Amit Kumar and Thiruvengadam, Kannan and Manikkam, Radhakrishnan and A. S., Shainaba and Balasubramanian, Mahizhaveni and Elango, Padmasini and Ebenezer Rajadas, Sam and Bharadwaj, Dinesh and Arumugam, Gandarvakottai Senthilkumar and Ganesan, Suresh and Kumar A. K., Hemanth and Singh, Manjula and Patil, Shripad and U. C. A., Jaleel and Doble, Mukesh and R., Balagurunathan and Tripathy, Srikanth Prasad and Kumar, Vanaja (2023) In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor. PLOS ONE, 18 (3). e0282454. ISSN 1932-6203

Radhakrishnan, R and Prabuseenivasan, S and Hannah, S and Vaishanavee, V and Senthildevi, V and Kannadhasan, T and Suchithra, R and Rajendran, P and Chinnaiyan, P and Shanmugam, S (2023) Genotype MTBDRsl Version 2 and Phenotypic Drug Resistance Detection of Mycobacterium tuberculosis for Fluoroquinolones and Aminoglycosides. Genotype MTBDRsl Version 2 and Phenotypic Drug Resistance Detection of Mycobacterium tuberculosis for Fluoroquinolones and Aminoglycosides, 12(3) (299-304).

Rajendran, P and Padmapriyadarsini, C and Shanmugam, S and Babu, S (2023) Molecular Characterisation of M. kansasii Isolates by Whole-Genome Sequencing. Molecular Characterisation of M. kansasii Isolates by Whole-Genome Sequencing, 12(10) (1249).

Rajendran, P and Shanmugam, S (2023) Comprehensive assessment of invalid and indeterminate results in Truenat MTB-RIF testing across sites under the national TB elimination program of India. Comprehensive assessment of invalid and indeterminate results in Truenat MTB-RIF testing across sites under the national TB elimination program of India, 11 (1255756).

Rajendran, P and Thiruvengadam, K and Shanmugam, s and Padmapriyadarsini, C (2023) Establishing proof of concept for utility of TrueprepV R-extracted DNA in line-probe assay testing. Establishing proof of concept for utility of TrueprepV R-extracted DNA in line-probe assay testing, 11 (1255756).

Sivakumar, Shanmugam (2023) Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity. Multi-drug loaded eugenol-based nanoemulsions for enhanced anti-mycobacterial activity, 14(3) (40584).

Subramanyam, Balaji and Chandrasekaran, Padmapriyadarsini (2023) Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes. Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes, 20(12) (1760-1768).

Thangavel, K and Vadivel, SD and Thiruvengadam, K. and Sivaramakrishnan, G and Padmapriyadarsini, C and Shanmugam, S (2023) Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India, 59(6) (1005).

This list was generated on Tue Aug 18 14:51:41 2026 IST.